ENTERA BIO IS-0000769 Market Cap ($432.85 Million)
Market Cap & Net Worth: ENTERA BIO IS-0000769 (5DT)
ENTERA BIO IS-0000769 market cap. ENTERA BIO IS-0000769 (F:5DT) has a market capitalization of $432.85 Million (€370.24 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #12687 globally and #1363 in its home market, demonstrating a 5.34% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ENTERA BIO IS-0000769's stock price €2.76 by its total outstanding shares 173141831 (173.14 Million). Also see cash efficiency ratio of ENTERA BIO IS-0000769 for how efficiently the company converts equity into cash flow.
ENTERA BIO IS-0000769 Market Cap History (2020–2026)
ENTERA BIO IS-0000769 market cap history from 2020 to 2026. Data shows growth from $165.99 Million to $558.68 Million (11.14% CAGR). Check ENTERA BIO IS-0000769 stock quote for real-time trading data and today's change.
ENTERA BIO IS-0000769 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ENTERA BIO IS-0000769's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ENTERA BIO IS-0000769 (5DT) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
7171.49x
ENTERA BIO IS-0000769's market cap is 7171.49 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $518.20 Million | $571.00K | -$12.19 Million | 907.53x | N/A |
| 2022 | $122.22 Million | $134.00K | -$13.07 Million | 912.10x | N/A |
| 2024 | $408.89 Million | $181.00K | -$9.54 Million | 2259.06x | N/A |
| 2025 | $301.20 Million | $42.00K | -$11.44 Million | 7171.49x | N/A |
Competitor Companies of 5DT by Market Capitalization
Companies near ENTERA BIO IS-0000769 in the global market cap rankings as of November 4, 2026. Also see balance sheet size of ENTERA BIO IS-0000769 for a full breakdown of the balance sheet.
Key companies related to ENTERA BIO IS-0000769 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ENTERA BIO IS-0000769 (2020–2026)
Market capitalization of ENTERA BIO IS-0000769 from 2020 to today. Between 2020 and today, ENTERA BIO IS-0000769's market cap moved from $165.99 Million to $ 558.68 Million, with a yearly change of 11.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €558.68 Million | +85.48% |
| 2025 | €301.20 Million | -26.34% |
| 2024 | €408.89 Million | +322.59% |
| 2023 | €96.76 Million | -20.83% |
| 2022 | €122.22 Million | -76.41% |
| 2021 | €518.20 Million | +212.20% |
| 2020 | €165.99 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ENTERA BIO IS-0000769 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $432.85 Million USD |
| MoneyControl | $432.85 Million USD |
| MarketWatch | $432.85 Million USD |
| marketcap.company | $432.85 Million USD |
| Reuters | $432.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ENTERA BIO IS-0000769
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a ta… Read more